[1] Chaka W, Heyderman R, Gangaidzo I, et al. Cytokine profiles in cerebrospinal fluid of human immunodeficiency virus-infected patients with cryptococcal meningitis:no leukocytosis despite high interleukin-8 levels. J Infect Dis, 1997, 176:1633-1636. [2] Dixon DM, Casadevall A, Klein B, et al. Development of vaccines and their use in the prevention of fungal infections. Med Mycol,1998, 36(Suppl 1):57-67. [3] Buchanan KL, Murphy JW. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun, 1993, 61:2854-2865. [4] Huffnagle GB, Yates JL, Lipscomb MF. T cell-mediated immunity in the lung:a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect Immun, 1991, 59:1423-1433. [5] Blasi E, Mazzolla R, Pitzurra L, et al. Protective effect of picolinic acid on mice intracerebrally infected with lethal doses of Candida albicans. Antimicrob Agents Chemother, 1993, 37:2422-2426. [6] Mazzolla R, Barluzzi R, Brozzetti A, et al. Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrob Agents Chemother, 1997, 41:802-807. [7] Blasi E, Barluzzi R, Mazzolla R, et al. Biomolecular events in volved in anticryptococcal resistance in the brain. Infect Immun,1995, 63:1218-1222. [8] 孙卫民,王惠琴主编.<细胞因子研究方法学>第1版,北京:人民卫生出版社出版,1999.352. [9] Lambros MP, Schafer F, Blackstock R, et al. Liposomes, a potential immunoadjuvant and carrier for a cryptococcal vaccine. J Pharm Sci, 1998, 87:1144-1148. [10] 郝光荣主编.<实验动物学>,第1版,第二军医大学出版社出版,1999年,105. [11] Blasi E, Barluzzi R, Mazzolla R, et al. Differential host susceptibility to intracerebral infections with Candida albicans and Cryptococcus neoformans. Infect Immun, 1993, 61:3476-3481. |